The adjustable PAB was found to improve early survival and also made delayed repair feasible in a better clinical state, with reduced mortality and morbidity.
Optimal anticoagulation strategy during cardiopulmonary bypass (CPB) remains uncertain in patients with heparin-induced thrombocytopenia (HIT) who require urgent/emergent cardiac surgery.
In this prospective randomized clinical study, the efficacy of these combined approaches on reducing blood loss and transfusion requirements was evaluated.
